Atea Pharmaceuticals (AVIR) vs Greenwich LifeSciences (GLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed Atea Pharmaceuticals (AVIR) over the past year, gaining 136.2% versus a gain of 33.3%. Over five years, GLSI leads with a -41.8% price change compared with -51.4% for AVIR. Atea Pharmaceuticals is the larger company by market cap ($318.0 million vs $282.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVIR | GLSI |
|---|---|---|
| Share price | $3.96 | $19.25 |
| Market cap | $318.00M | $282.56M |
| 1-day change | +0.76% | -2.73% |
| YTD return | +10.92% | -8.38% |
| 1-year return | +33.33% | +136.20% |
| 5-year return | -51.35% | -41.84% |
| EPS (TTM) | $-1.95 | $-1.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-158.35M | $-19.36M |
| 52-week high | $6.45 | $34.10 |
| 52-week low | $2.96 | $7.78 |
| Distance from 52-week high | -38.60% | -43.55% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +127.27% | +198.70% |
| Average volume | 290.60K | 160.76K |
| Shares outstanding | 80.30M | 14.68M |
| Employees | 55 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed AVIR by 102.9 percentage points over the past year.
About Atea Pharmaceuticals
AVIR stock →Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
AVIR vs GLSI FAQ
Which is bigger, Atea Pharmaceuticals or Greenwich LifeSciences?
Atea Pharmaceuticals (AVIR) is larger, with a market capitalization of $318.00M compared with $282.56M for Greenwich LifeSciences (GLSI).
Which stock has performed better over the past year, AVIR or GLSI?
GLSI returned +136.20% over the past 12 months, compared with +33.33% for AVIR (price return, excluding dividends). Past performance does not predict future results.
Are Atea Pharmaceuticals and Greenwich LifeSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.